GXGui-Lian Xu

Gui-Lian Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gui-Lian Xu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Xu

    Department of Immunology, Basic Medicine College Army Medical University Chongqing China

    5 shared publications
  • Gui-Qing Li

    Department of Immunology, Army Medical University (Third Military Medical University), Chongqing 400038, China

    4 shared publications
  • Quan-You Zheng

    Department of Urology, 958th Hospital of PLA, Army Medical University, Chongqing, China

    4 shared publications
  • Shun Wu

    Department of Nephrology, Huaihai Hospital affiliated with Xuzhou Medical University, Xuzhou 221004, China

    4 shared publications
  • Jian Chen

    Department of Immunology, Basic Medicine College Army Medical University Chongqing China

    3 shared publications
  • Ming Tang

    Urinary Nephropathy Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

    3 shared publications

Latest Publications

  • Open Access

    Environmental toxicant ochratoxin A induces psoriasis based on network toxicology machine learning and molecular docking analyses

    by Jian Hu, Ming Tang, Quan-You Zheng, Shen-Ju Liang, Gui-Lian Xu, Ke-Qin Zhang

    Psoriasis is a chronic skin disease influenced by genetic susceptibility and environmental factors. Ochratoxin A (OTA) is a ubiquitous foodborne mycotoxin known for its immunotoxicity, however, its specific role in psoriasis pathogenesis remains underexplored. This study implemented an integrated systems biology framework that combined network toxicology, machine learning, and molecular dynamics to elucidate the mechanisms of OTA-induced psoriasis. By intersecting OTA-associated targets with psoriasis-related genes, we identified 242 potential targets that were significantly enriched in the IL-17 and TNF signaling pathways. We utilized a weighted gene co-expression network analysis combined with nine machine learning algorithms to identify five hub genes based on their high feature importance and diagnostic robustness: PNP, LCN2, HSPE1, TYMP, and CXCR2, with an area under the curve of 0.988 in the training set and 1.00 in the external validation. These hub genes positively correlated with activated dendritic cells and eosinophils, suggesting that they mediate a pro-inflammatory microenvironment. Molecular docking and dynamics simulations demonstrated stable binding affinities (up to − 8.8 kcal/mol) between OTA and the corresponding proteins. Our findings establish a mechanistic link whereby OTA directly interacts with key regulatory proteins to drive immune dysregulation, providing novel biomarkers and a theoretical basis for managing OTA-induced psoriasis.

  • Open Access

    TNFSF14‐HVEM/LTβR Exacerbates Keratinocyte Abnormalities and IMQ‐Induced Psoriatic Skin Inflammation via Activating NF‐κB/TWIST1 Signalling Pathway

    by Sheng‐Jie Long, Quan‐You Zheng, Feng Xu, Gui‐Qing Li, Jian Chen, Wen‐Jie Chen, Jiang‐Mei Xu, Xiao‐Lin Gao, Shen‐Ju Liang, Gui‐Lian Xu

    Psoriasis (PS) is a chronic autoimmune skin disease that poses a serious threat to over 100 million patients worldwide. An increasing number of studies have indicated that keratinocytes (KCs) play an essential role in the inflammatory progression of PS. The present study found that tumour necrosis factor superfamily member 14 (TNFSF14) and its two receptors were up‐regulated in IMQ‐primed KCs and psoriatic skin sections. It also revealed that blocking TNFSF14 signalling (via gene knockout or injections) with its receptors' soluble fusion proteins lymphotoxin beta receptor (LTβR)–immunoglobulin G Fc domain (LTβR‐IgGFc) and herpesvirus entry mediator–IgGFc (HVEM‐IgGFc) significantly alleviated imiquimod (IMQ)‐induced psoriatic skin inflammation by attenuating epidermal hyperplasia, decreasing cellular proliferation, keratinisation, apoptosis, and inflammatory response. Accordingly, direct stimulation with recombinant TNFSF14 markedly enhanced KC abnormalities as evidenced by aggravated cell proliferation and keratinisation, increased cellular apoptosis, and up‐regulated inflammatory cytokine expression. Mechanistic studies demonstrated that TNFSF14 mediates KC abnormalities via the nuclear factor‐kappa B (NF‐κB)/TWIST1 pathway. Taken together, our study findings indicate that TNFSF14‐HVEM/LTβR promotes KC dysfunction and IMQ‐induced psoriatic skin inflammation via enhancing NF‐κB/TWIST1 signalling and suggest that TNFSF14 is a promising therapeutic strategy for the clinical treatment of PS.


  • Human mesenchymal stromal cells ameliorate cisplatin-induced acute and chronic kidney injury via TSG-6

    by Ming Tang, Linguo Shen, Maozhi Tang, Ling Liu, Zhengsheng Rao, Zhilin Wang, Yadi Wang, Supei Yin, Shujing Li, Guilian Xu, et al.

    Cisplatin is widely employed in tumor chemotherapy, but nephrotoxicity is an unavoidable side effect of cisplatin. Several studies have demonstrated that mesenchymal stromal cells (MSCs) ameliorate cisplatin-induced kidney injury, but the underlying mechanisms are unknown. In this study, the cisplatin-induced kidney injury mouse model was established by subjecting a single intraperitoneal injection with cisplatin. One hour before cisplatin injection, the mice received human bone marrow MSCs (hBM-MSCs) with or without siRNA-transfection, recombinant human tumor necrosis factor (TNF)-α-stimulated gene/protein 6 (rhTSG-6), or PBS through tail vein. In addition, cisplatin-stimulated HK-2 cells were treated with hBM-MSCs or rhTSG-6. hBM-MSCs treatment remarkably ameliorated cisplatin-induced acute and chronic kidney injury, as evidenced by significant reductions in serum creatinine (Scr), blood urea nitrogen (BUN), tubular injury, collagen deposition, α-smooth muscle actin accumulation, as well as inflammatory responses, and by remarkable increased anti-inflammatory factor expression and Treg cells infiltration in renal tissues. Furthermore, we found that only a few hBM-MSCs engrafted into damaged kidney and that the level of human TSG-6 in serum of mice increased significantly following hBM-MSCs administration. Moreover, hBM-MSCs significantly increased the viability of damaged HK-2 cells and decreased the levels of inflammatory cytokines in the culture supernatant. However, knockdown of TSG-6 gene in hBM-MSCs significantly attenuated their beneficial effects in vivo and in vitro. On the contrary, treated with rhTSG-6 achieved similar beneficial effects of hBM-MSCs. Our results indicate that systemic administration of hBM-MSCs alleviate cisplatin-induced acute and chronic kidney injury in part by paracrine TSG-6 secretion.


  • LIGHT deficiency aggravates cisplatin-induced acute kidney injury by upregulating mitochondrial apoptosis

    by Yan Yang, Li Meng, Shun Wu, You Li, Yu Zhong, Feng Xu, Xiao-Cui Zhou, Gui-Qing Li, Gui-Lian Xu, Kan-Fu Peng


  • Open Access

    Fibrinogen-like protein 2 deficiency aggravates renal fibrosis by facilitating macrophage polarization

    by Shun Wu, Meng Li, Feng Xu, Gui-Qing Li, Bo Han, Xian-Dong He, Shu-Jing Li, Qian-Hui He, Xin-Yue Lai, Shuo Zhou, et al.


  • Complement component 3 prevents imiquimod-induced psoriatic skin inflammation by inhibiting apoptosis in mice

    by Quan-You Zheng, Shen-Ju Liang, Feng Xu, Yi Yang, Jian-Li Feng, Fen Shen, Yu Zhong, Shun Wu, Yong Shu, Dao-Dong Sun, et al.


  • Open Access

    C5a/C5aR1 mediates IMQ‐induced psoriasiform skin inflammation by promoting IL‐17A production from γδ‐T cells

    by Quan‐You Zheng, Feng Xu, Yi Yang, Dao‐Dong Sun, Yu Zhong, Shun Wu, Gui‐Qing Li, Wei‐Wu Gao, Tao Wang, Gui‐Lian Xu, et al.

    Psoriasis is a chronic relapsing inflammatory skin disease, affecting up to 3% of the global population. Accumulating evidence suggests that the complement system is involved in its pathogenesis. Our previous study revealed that the C5a/C5aR1 pathway is crucial for disease development. However, the underlying mechanisms remain largely unknown. To explore potential mechanisms, psoriatic skin lesions and histological changes were assessed following imiquimod (IMQ) cream treatment. Inflammatory cytokine expression was tested by real‐time RT‐PCR. Immunohistochemistry and flow cytometry were used to identify inflammatory cell infiltration and interleukin (IL‐17A) IL‐17A expression. A C5aR1 antagonist (C5aR1a) and PI3K inhibitor (wortmannin) were used for blocking experiments (both in vivo and in vitro) to explore the mechanism. C5a/C5aR1‐pathway inhibition significantly attenuated psoriasis‐like skin lesions with decreased epidermal hyperplasia, downregulated type 17‐related inflammatory gene expression, and reduced IL‐17A‐producing γδ‐T cell responses. Mechanistically, C5a/C5aR1 promoted the latter phenotype via PI3K‐Akt signaling. Consistently, C5aR1 deficiency clearly ameliorated IMQ‐induced chronic psoriasiform dermatitis, with a significant decrease in IL‐17A expression. Finally, blocking C5aR1 signaling further decreased psoriasiform skin inflammation in IL‐17‐deficient mice. Results suggest that C5a/C5aR1 mediates experimental psoriasis and skin inflammation by upregulating IL‐17A expression from γδ‐T cells. Blocking C5a/C5aR1/IL‐17A axis is expected to be a promising strategy for psoriasis treatment.


  • Open Access

    Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression

    by Ming Tang, Xu Cao, Kun Zhang, You Li, Quan-You Zheng, Gui-Qing Li, Qian-Hui He, Shu-Jing Li, Gui-Lian Xu, Ke-Qin Zhang

    Renal fibrosis is the final manifestation of various chronic kidney diseases, and no effective therapy is available to prevent or reverse it. Celastrol, a triterpene that derived from traditional Chinese medicine, is a known potent anti-fibrotic agent. However, the underlying mechanisms of action of celastrol on renal fibrosis remain unknown. In this study, we found that celastrol treatment remarkably attenuated unilateral ureteral obstruction (UUO)-induced mouse renal fibrosis. This was evidenced by the significant reduction in tubular injury; collagen deposition; accumulation of fibronectin, collagen I, and α-smooth muscle actin; and the expression levels of pro-fibrotic factors Vim, Cola1, and TGF-β1 mRNA, as well as inflammatory responses. Celastrol showed similar effects in a folic acid-induced mouse renal fibrosis model. Furthermore, celastrol potentiated the expression of the anti-fibrotic factor cannabinoid receptor 2 (CB2R) in established mouse fibrotic kidney tissues and transforming growth factor β1 (TGF-β1)-stimulated human kidney 2 (HK-2) cells. In addition, the CB2R antagonist (SR144528) abolished celastrol-mediated beneficial effects on renal fibrosis. Moreover, UUO- or TGF-β1-induced activation of the pro-fibrotic factor SMAD family member 3 (Smad3) was markedly inhibited by celastrol. Inhibition of Smad3 activation by an inhibitor (SIS3) markedly reduced TGF-β1-induced downregulation of CB2R expression. In conclusion, our study provides the first direct evidence that celastrol significantly alleviated renal fibrosis, by contributing to the upregulation of CB2R expression through inhibiting Smad3 signaling pathway activation. Therefore, celastrol could be a potential drug for treating patients with renal fibrosis.


  • Complement C5a/C5aR pathway potentiates the pathogenesis of gastric cancer by down-regulating p21 expression

    by Jian Chen, Gui-Qing Li, Li Zhang, Ming Tang, Xu Cao, Gui-Lian Xu, Yu-Zhang Wu